Elanco Animal Health (NYSE:ELAN) Issues FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.800-0.860 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its FY25 guidance to $0.80-$0.86 EPS.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of recent analyst reports. Barclays raised their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Stock Down 5.1 %

Shares of NYSE:ELAN traded down $0.56 during midday trading on Tuesday, reaching $10.55. 1,252,305 shares of the company were exchanged, compared to its average volume of 4,574,833. The firm has a market cap of $5.21 billion, a PE ratio of 26.34, a P/E/G ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a fifty-two week low of $10.20 and a fifty-two week high of $18.80. The stock has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $13.09. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $0.08 earnings per share. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.